Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

27.75 +0.08 (+0.31%)
Streaming Delayed Price Updated: 11:58 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 Next >
News headline image
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
From Roivant Sciences
Via GlobeNewswire
News headline image
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
From Roivant Sciences
Via GlobeNewswire
News headline image
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics 
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
From Roivant Sciences
Via GlobeNewswire
News headline image
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. 
From Roivant Sciences
Via GlobeNewswire
News headline image
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.